BlackRock Fund Advisors’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

BlackRock Fund Advisors’s Portfolio ZYNE Stock Details ZYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$306K	Sell	19,623 -6,116	-24%	-$82.4K	﹤0.01%	3326
2016 Q3	$336K	Buy	25,739 +8,861	+53%	+$84.2K	﹤0.01%	3308
2016 Q2	$116K	Sell	16,878 -73,227	-81%	-$613K	﹤0.01%	3631
2016 Q1	$851K	Sell	90,105 -5,115	-5%	-$41.3K	﹤0.01%	3197
2015 Q4	$959K	Buy	95,220 +12,742	+15%	+$169K	﹤0.01%	3236
2015 Q3	$1.18M	Buy	+82,478	New	+$2.02M	﹤0.01%	3194

Other funds holding ZYNE

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

CCMU

Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

AAM

Auxier Asset Management Aurora, Oregon $696M AUM 18.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BlackRock Fund Advisors's ZYNE Position: Q4 2016 in Review

BlackRock Fund Advisors reduced its Zynerba Pharmaceuticals, Inc (ZYNE) stake by 24% in Q4 2016, selling an estimated $82.4K and leaving 19,623 shares worth $306K. The position accounts for ﹤0.01% of the portfolio, ranked #3326.

BlackRock Fund Advisors first reported a position in ZYNE in Q3 2015 and has held it in 6 quarters since. The position peaked at $1.18M in Q3 2015. 34 funds tracked by Wall St. Rank hold ZYNE as of Q4 2016.

BlackRock Fund Advisors held 19,623 shares of Zynerba Pharmaceuticals, Inc worth $306K as of Q4 2016.
BlackRock Fund Advisors sold 6,116 Zynerba Pharmaceuticals, Inc shares in Q4 2016, an estimated $82.4K.
Zynerba Pharmaceuticals, Inc made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #3326 holding.
BlackRock Fund Advisors first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2015 and has held it in 6 quarters since.
BlackRock Fund Advisors's Zynerba Pharmaceuticals, Inc position peaked at $1.18M in Q3 2015.
34 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.